Valby, Denmark, 2017-03-30 13:09 CEST (GLOBE NEWSWIRE) -- Valby, Denmark, 30 March 2017 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Directors was adopted and the annual report was approved.
The proposal to distribute a dividend of 40% of the net profit for the accounting year 2016, corresponding to DKK 2.45 per share, or a total dividend of DKK 484 million, was adopted.
Lars Rasmussen, Lene Skole, Lars Holmqvist and Jesper Ovesen were re-elected to the Board of Directors. In addition, Jeremy M. Levin was elected to the Board of Directors. Terrie Curran did not stand for re-election. Immediately after the General Meeting, the Board of Directors elected Lars Rasmussen as Chairman and Lene Skole as Deputy Chairman of the Board of Directors.
The Board of Directors of Lundbeck will hereafter comprise:
After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.
Jesper Ovesen, Lars Rasmussen and Lars Holmqvist were elected as members of the Audit Committee. Lars Rasmussen and Lene Skole were elected as members of the Remuneration Committee. Jeremy M. Levin and Lene Skole were elected as members of the Scientific Committee.
The General Meeting approved the remuneration for the Board of Directors for the year 2017.
Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.
The proposal to give the Board of Directors authorization to let the company acquire own shares of a total nominal value of up to 10% of the share capital was adopted.
The Chairman of the General Meeting was authorised to file for registration the resolutions passed at the general meeting with the Danish Business Authority.
No other business was on the agenda at the Annual General Meeting.
The Board of Directors
|Palle Holm Olesen||Mads Kronborg|
|Vice President, Investor Relations||Senior Director, Corp. Communication|
|+45 30 83 24 26||+45 36 43 40 00|
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.
Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.2 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.
Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.
Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.
Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.